Search

The prevalence of neurological dieases, including neurodegenerative, neurotraumatic disorders, and neuroinflammatory conditions, has been rising due to global population and aging demographics. A key factor in the pathogenesis of these disorders is the hyperaccumulation of reactive oxygen and nitrogen species (RONS). Nanozymes have emerged as promising candidates for neurotherapeutic applications owing to their exceptional catalytic activity and stability. Of particular note is their ability to cross the blood‐brain barrier and counteract the production of reactive oxygen species via their enzyme‐mimicking characteristics. In this review, the latest advancements and theoretical knowledge in this research domain are summarized. Using the inherent functionalities of the Web of Science and bibliometric methodologies, annual publication trends are identified and extensively explored the most researched topics and neurological disorders in this field. The antioxidant reduction chemistry of the nanozymes is discussed, highlighting their ability to mimic natural oxidoreductase activity and inhibit RONS production at the source. Moreover, this review delves into the current limitations and future prospects of these mechanisms in addressing neurological disorders. The significant benefits and recent developments in the use of RONS‐regulating nanozymes for the treatment of neurological diseases are emphasized, offering insights into their therapeutic applications and broader implications for neurology. [ABSTRACT FROM AUTHOR]

We reported a polyoxometalate-based heterojunction (GdP 5 W 30 @WS 2) with shifting or mixed redox states (W6+/W5+) that can realize near-infrared (NIR) Light-facilitated photocatalytic W6+/W5+ redox cycling for enhanced POD-like catalytic activity and photothermal therapy of bacterial infections. [Display omitted] • GdP 5 W 30 @WS 2 , a polyoxometalate-based heterojunction nanocomposite with peroxidase (POD)-like catalytic activity, was introduced to treat bacteria-infected diseases. • Near-infrared (NIR) laser-enhanced POD-like catalytic activity of GdP 5 W 30 @WS 2 was achieved via NIR-driven photocatalytic W6+/W5+ rapid redox cycling. • This nanocomposite also exhibited excellent photothermal effect and glutathione (GSH) exhaustion performance for more effective reactive oxygen species (ROS) production. • GdP 5 W 30 @WS 2 realized chemodynamic/photothermal performance amplified with NIR-photocatalytic action for considerabled biofilm microenvironment (BME)-activated synergistic therapy. Metal-based nanomaterials with shifting or mixed redox states have been widely applied for combating against bacteria-infected diseases by virtue of their peroxidase (POD)-like catalytic activity. Herein, a polyoxometalate-based heterojunction (GdP 5 W 30 @WS 2) with shifting or mixed redox states (W6+/W5+) is devised to achieve boosted reactive oxygen species (ROS) generation by near-infrared (NIR) laser-facilitated W6+/W5+ redox cycling for accelerated bacteria-infected wound healing. On the one hand, under the exposure to NIR laser, WS 2 as electron donor could be stimulated to transfer electrons to GdP 5 W 30 , which promotes the reduction from W6+ to W5+ active sites on the surface of the GdP 5 W 30. Consequently, the regenerated W5+ active sites could catalyze endogenous overexpressed H 2 O 2 to persistently generate ROS, which displays enhanced POD-like catalytic activity for chemodynamic therapy (CDT) by NIR-driven photocatalytic W6+/W5+ redox cycling. Moreover, GdP 5 W 30 @WS 2 also displays favorable glutathione (GSH)-activated photothermal performance by W6+-triggered GSH exhaustion for sufficient ROS generation, thereby facilitating the synergistic therapeutic efficiency of photothermal therapy (PTT) and CDT. We expect that the present work will promote the development of the heterojunction with shifting or mixed redox states for biofilm elimination based on NIR-facilitated enzyme-like catalytic activity, which may act as a candidate for BME-activated synergistic therapy. [ABSTRACT FROM AUTHOR]